We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Intracellular fate of micro- and nanoplastics in human placenta: Organelle-specific toxicity and mechanistic convergence
Summary
Scientists have found tiny plastic particles (microplastics and nanoplastics) inside the placenta, and this review pulls together existing research to explain what might be happening at a cellular level: these particles seem to overwhelm cells' waste-disposal systems, damage their energy-producing mitochondria, and trigger stress responses that don't fully shut off. This matters because the placenta is what nourishes and protects a developing baby, so if plastics are disrupting its cells this way, it could have implications for fetal development, though this is a proposed theoretical model based on current evidence, not a confirmed cause-and-effect finding, and more
Detection of micro- and nanoplastics (MNPs) in human placental tissue, fetal cord blood, and neonatal meconium marks a paradigm shift in prenatal exposure research. Yet the field lacks a mechanistic framework integrating the intracellular stress responses MNPs provoke subcellularly. This narrative review proposes an organelle-resolved model of MNP-induced cellular toxicity wherein internalized MNPs traffic through the endosomal-lysosomal system, initiating lysosomal overload and autophagic flux blockade, mitochondrial cristae disorganization consistent with ΔΨm collapse, and endoplasmic reticulum cisternal dilation with pro-apoptotic UPR switching. These converge into a unified framework - the chronic 'Plasticenta' cell danger response (cPCDR) - wherein MNP persistence is hypothesized to generate a perpetually re-triggered, incompletely resolved danger state. The Pi-GAC-glutaminolysis axis is proposed as a secondary metabolic convergence downstream of ΔΨm collapse. Contextualized within the DoHaD framework, the fetoplacental unit is positioned as a critical transgenerational MNP biosensor. Priority directions include scRNA-seq-based cPCDR validation, trophoblast organoid models, and prospective placental biobanking.